Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Marginal Zone B-cell Lymphoma (MALT Lymphoma).

Patrick D. Hung1, Mitchell L. Schubert, Anastasios A. Mihas

  • 1Division of Gastroenterology; 111N, McGuire VAMC, 1201 Broad Rock Boulevard, Richmond, VA 23249, USA. mitchell.schubert@med.va.gov

Current Treatment Options in Gastroenterology
|March 11, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Zollinger-Ellison Syndrome.

Current treatment options in gastroenterology·2003
Same journal

Esophageal Disorders in the Older Adult.

Current treatment options in gastroenterology·2025
Same journal

Endobariatrics: a Still Underutilized Weight Loss Tool.

Current treatment options in gastroenterology·2023
Same journal

Management of Post Ablative Barrett's Esophagus: a Review of Current Practices and Look at Emerging Technologies.

Current treatment options in gastroenterology·2023
Same journal

Inflammatory Bowel Disease Therapy and Venous Thromboembolism.

Current treatment options in gastroenterology·2023
Same journal

Ileal Pouch-Anal Anastomosis in the Older Adult: a Review of Postoperative Outcomes and Pouchitis Treatment.

Current treatment options in gastroenterology·2023
Same journal

Celiac Disease in the Elderly.

Current treatment options in gastroenterology·2023
See all related articles

Marginal zone B-cell lymphoma (MZBL) of the stomach, formerly MALT lymphoma, is a slow-growing cancer linked to H. pylori. Eradicating H. pylori can lead to remission in early stages.

Area of Science:

  • Gastroenterology
  • Oncology
  • Pathology

Background:

  • Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach is now preferred to be called marginal zone B-cell lymphoma (MZBL).
  • MZBL is characterized by the lymphoepithelial lesion and is associated with Helicobacter pylori infection.
  • This lymphoma is typically slow-growing, often localized, and generally has a favorable prognosis.

Purpose of the Study:

  • To clarify the preferred terminology for gastric MALT lymphoma.
  • To describe the etiology, characteristics, staging, and treatment of MZBL.
  • To highlight the role of H. pylori eradication in managing early-stage disease.

Main Methods:

  • Review of current literature and diagnostic criteria for gastric MZBL.
  • Description of staging procedures including endoscopy with biopsy, CT scans, and endoscopic ultrasound.

Related Experiment Videos

  • Summary of treatment modalities for limited and extensive disease.

    • Main Results:

    • Preferred terminology is marginal zone B-cell lymphoma (MZBL).
    • Helicobacter pylori eradication is an effective treatment for limited disease, leading to remission.
    • Surgery, chemotherapy, and radiation are successful for patients failing eradication or with extensive disease.

    Conclusions:

    • Gastric MZBL is a distinct entity with a good prognosis, often linked to H. pylori.
    • H. pylori eradication is a primary treatment for early-stage MZBL.
    • Multimodal therapy is effective for advanced or refractory cases of MZBL.